The 20th International Congress of Collateral Diseases was held? Professor Yang Yuejin: Tongxinluo solved two major international problems in the treatment of myocardial infarction!

[ad_1]

Inherit the essence, innovate and break through, transform the results, and go global. On February 24, the 20th International Collateral Congress was held grandly in Shijiazhuang, the “Medicine Capital of North China”. Nearly 20 academicians of the two academies, including Academicians Liu Depei, Academician Zhang Boli, Academician Yang Baofeng, Academician Wu Yiling, and Academician Yu Jinming, as well as more than 100,000 medical experts, scholars and industry colleagues from home and abroad gathered at the conference online and offline to discuss the network of traditional Chinese medicine. Major research, important results, and major new academic breakthroughs related to the transformation of disease theory!

Main venue of the 20th International Congress of Collateral Medicine

At the meeting, Professor Yang Yuejin from Fuwai Hospital of the Chinese Academy of Medical Sciences gave a speech entitled “Research Breakthrough on Tongxinluo in Preventing and Treating Myocardial No-Reflow and Reperfusion Injury in AMI – From Dual/Bidirectional Protection of Microvessels/Myocardium to Clinical Efficacy of CTS-AMI Research” academic report, sharing the major achievements of the “China Tongxinluo Myocardial Protection Research in the Treatment of Acute Myocardial Infarction” led by him. Research results show that Tongxinluo can significantly improve the 30-day and 1-year clinical prognosis of patients with ST-segment elevation myocardial infarction (STEMI), solving the two major international problems of “myocardial no-reflow” and “reperfusion injury.” Research The result is an important breakthrough in the treatment of acute myocardial infarction in the past 20 years!

Professor Yang Yuejin from Fuwai Hospital, Chinese Academy of Medical Sciences gave an academic report

“Myocardial no-reflow” and “reperfusion injury” are two major international problems that seriously affect patient survival rate

Cardiovascular disease is a disease that seriously endangers people’s health and life safety, ranking first among the total causes of death among urban and rural residents in my country. In the past 30 years, its incidence, prevalence and mortality have shown an overall upward trend. Among them, myocardial infarction is one of the major diseases causing death and disability worldwide. Acute ST-segment elevation myocardial infarction is dangerous and has a high mortality rate, and has become a major disease that seriously threatens public life and health.

Professor Yang Yuejin pointed out in the report: “In clinical practice, for ST-segment elevation myocardial infarction, the international consensus is that reperfusion therapy is the first choice, including emergency interventional therapy or thrombolytic therapy. However, after treatment, some patients develop symptoms of myocardial ischemia. There is still no significant improvement, and the heart function cannot be restored well.” The reason why this happens is because interventional or thrombolytic treatment only opens the large blood vessels of the heart, and there is no gap between the large blood vessels and myocardial cells. , there are still many tiny blood vessels, which are the last channels to transport blood to myocardial cells. However, due to ischemia and hypoxia, many of these tiny blood vessels have become necrotic and can no longer deliver nutrients to the myocardial cells in the infarct area. Therefore, the risk of myocardial infarction is The symptoms still cannot be improved well, and the above phenomenon is called “myocardial no-reflow” by the medical community; at the same time, although some patients have restored myocardial perfusion, the myocardial damage has worsened, which is called “reperfusion injury”. .

Professor Yang Yuejin pointed out in his report that “myocardial no-reflow” and “reperfusion injury” are two major problems in the world.

Professor Yang Yuejin mentioned that “myocardial no-reflow” and “reperfusion injury” can lead to serious myocardial damage, progressive left ventricular dilation, severe arrhythmia, congestive heart failure and other hazards, seriously affecting the patient’s postoperative survival rate.

Professor Yang Yuejin emphasized that these two problems are still two major international problems in the treatment of myocardial infarction. Currently, there is still a lack of specific therapeutic drugs to prevent and treat these problems globally. There is an urgent need for new drugs or new treatment strategies in clinical practice to improve ST. Current status of treatment for patients with segment elevation myocardial infarction.

Tongxinluo protects myocardium and endothelial cells in both directions, preventing and treating myocardial no-reflow and reperfusion injury.

“Protecting endothelial cells is the key to preventing and treating myocardial no-reflow,” Professor Yang Yuejin pointed out. Tongxinluo is a representative drug widely used in China to treat cardiovascular and cerebrovascular diseases. Over the years since its launch, a series of studies have been conducted on cardiovascular diseases and cerebrovascular diseases. Previous studies have shown that Tongxinluo can significantly reduce myocardial no-reflow and infarct size, protect myocardial cells, and exhibit good efficacy and safety.

Professor Yang Yuejin pointed out in his report that Tongxinluo has the effect of protecting vascular endothelium.

Professor Yang Yuejin introduced that research has found that Tongxinluo can significantly protect the structural and functional integrity of microvessels during ischemia-reperfusion in acute myocardial infarction. It not only protects endothelial cells and myocardial cells through endothelial cells, but also proves that it directly protects myocardial cells. Previously, Professor Yang Yuejin talked about the experiment in an interview with the media: “Myocardial cells and endothelial cells are closely connected. When Tongxinluo protects myocardial cells, it can also notify the endothelial cells. It will say, ‘Brother, I am hurt now. , you have to protect yourself’, the endothelial cells say ‘ok, don’t worry’, and it immediately starts to protect itself, and in turn protects the cardiomyocytes.”

Professor Yang Yuejin pointed out: “The ‘China Tongxinluo Myocardial Protection Study in the Treatment of Acute Myocardial Infarction’ included 3,797 patients with ST-segment elevation myocardial infarction (STEMI) within 24 hours of onset in 124 hospitals across the country. The results showed that Tongxinluo has a significant effect. Reduce the risk of major adverse cardiovascular and cerebrovascular events (including cardiovascular death, repeat myocardial infarction, emergency coronary revascularization and stroke) by 36% in 30 days, and reduce the risk of cardiovascular death by 30%; Tongxinluo continued to reduce the risk after 1 year of study The risk of adverse cardiovascular and cerebrovascular events is 36%, and the risk of cardiovascular death is reduced by 27%, providing effective therapeutic drugs to improve the long-term prognosis of acute myocardial infarction.”

To win the top international journal is a major breakthrough in the treatment of acute myocardial infarction in the past 20 years!

Professor Yang Yuejin said that the research lasted for five years and was a sub-project of the national key research and development plan “Research on the Intervention of Cardiovascular Event Chain by the Guidance System of Choroid Theory and Health Theory”. The research paper was published in the “Journal of the American Medical Association” with an impact factor of 120.7. (JAMA)” was published. JAMA, together with the New England Journal of Medicine, The Lancet and the British Medical Journal, is one of the four major medical journals in the world.

The paper “Research on Myocardial Protection of Chinese Tongxinluo in the Treatment of Acute Myocardial Infarction” was published in the top international medical journal “JAMA”

This study won the title of the main journal of “JAMA” and is a major breakthrough in the research of evidence-based medicine in traditional Chinese medicine. It is a milestone in the modernization process of traditional Chinese medicine. It demonstrates the scientific research and innovation strength of Chinese researchers in the new era and is a step forward for the internationalization of traditional Chinese medicine. A solid step forward.

Professor Eric Peterson of the University of Texas Southwestern Medical Center, a participant in the study, once said that this is a very high-quality randomized, double-blind, controlled clinical trial, which is very consistent with foreign Western medical standards. This is a paper related to traditional Chinese medicine. First published in the world’s leading magazine. Richard Bach of the University of Washington School of Medicine mentioned in JAMA’s “Editor’s Note” that this will have very important significance and impact on the treatment of acute myocardial infarction patients around the world. This represents a very significant development in the treatment of acute myocardial infarction in the past 20 years. breakthrough.

The advent of Tongxinluo is not just a new drug in the general sense, but represents the emergence of a new theory to guide the prevention and treatment of vascular lesions. The successful development of Tongxinluo has set off a research boom around the theory of collateral diseases and drugs to unblock collaterals. Up to now, a total of more than 13,500 Chinese and English articles related to Tongxinluo have been published, including more than 120 SCI articles. A large number of basic studies have shown that Tongxinluo has a full protective effect on blood vessels and has a wide range of effects on different pathological links of vascular lesions.

“When traditional Chinese medicine goes global, culture must go first.” As the treasure house of traditional medicine in my country, traditional Chinese medicine culture has lasted for a long time. With the advancement of science and technology, innovative traditional Chinese medicine has gradually attracted people’s attention. The annual International Collateral Congress is not only an important exchange platform for sharing new academic achievements in the domestic and foreign medical fields, but also an important way for traditional Chinese medicine culture to go global.

[ad_2]

Source link